Introduction
In the fight against the Omicron variant of COVID-19, a new mRNA booster vaccine has been launched in the country. Developed by Genova using indigenous technology, GEMCOVAC-OM is the first booster vaccine specifically designed to target the Omicron variant. One of its remarkable features is that it can be administered without the use of a needle, offering convenience and ease of administration. This article delves into the details of GEMCOVAC-OM, its development, unique characteristics, and the significance of this new addition in the battle against COVID-19.
GEMCOVAC-OM: A Needle-Free mRNA Booster Vaccine
Development by Genova
GEMCOVAC-OM has been developed by Genova, an Indian company at the forefront of vaccine research and development. Using indigenous technology, Genova has successfully created this mRNA-based booster vaccine to combat the Omicron variant.
Emergency Use Authorization
The vaccine has recently received emergency use authorization from the Drug Controller General of India (DCGI), highlighting its effectiveness and safety in targeting the Omicron variant. This authorization paves the way for its widespread use and distribution.
Financial Assistance and Support
GEMCOVAC-OM has received financial assistance from the Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC). This support showcases the government’s commitment to promoting indigenous vaccine development and combating the challenges posed by COVID-19.
GEMCOVAC-OM and the Atmanirbhar Bharat Initiative
Atmanirbhar Bharat 3.0 Package
GEMCOVAC-OM is the fifth vaccine developed under the Atmanirbhar Bharat 3.0 package. This package aims to rapidly develop COVID-19 vaccines and strengthen India’s self-reliance in healthcare. GEMCOVAC-OM’s creation and inclusion in this initiative highlight its significance in the nation’s fight against the pandemic.
Mission “COVID Suraksha”
The development and launch of GEMCOVAC-OM fall under the implementation of the mission “COVID Suraksha” by DBT and BIRAC. This mission focuses on ensuring the safety and protection of the population through the development and deployment of effective vaccines. GEMCOVAC-OM’s availability contributes to the mission’s objective of safeguarding the nation against the Omicron variant.
Unique Features of GEMCOVAC-OM
Needle-Free Administration
One of the notable features of GEMCOVAC-OM is its needle-free administration. Unlike traditional vaccines that require a needle, GEMCOVAC-OM utilizes an intradermal delivery system called “Tropis.” This innovative approach enhances convenience and minimizes discomfort during the vaccination process.
Thermostability
Unlike many mRNA vaccines that necessitate extremely cold temperatures for storage and transportation, GEMCOVAC-OM is a thermostable vaccine. It remains stable at temperatures between 2 to 8 degrees Celsius, making it easier to handle and distribute across various regions, including those with limited cold chain infrastructure.
